Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05497531 · ClinicalTrials.gov registry record · NA

Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

A NA study of Pancreatic Cancer and Hepatocellular Carcinoma, sponsored by University of California, Irvine.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT05497531 is a NA study of Pancreatic Cancer and Hepatocellular Carcinoma that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 15 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05497531, a NA study of Pancreatic Cancer and Hepatocellular Carcinoma, is actively recruiting participants, sponsored by University of California, Irvine.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.

Interventions

  • DIAGNOSTIC_TEST ctDNA Blood Collection

Study Locations (1)

California

  • Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-09-07
Est. Completion 2026-06
Phase NA

Sponsor

University of California, Irvine

368 total trials

What the Registry Record Tells You About NCT05497531

The ClinicalTrials.gov registry entry for NCT05497531 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which ctDNA Blood Collection is the first listed.

NCT05497531 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05497531 about?

NCT05497531 is a clinical study titled "Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers". This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.

What is the current status of trial NCT05497531?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2022-09-07. Estimated completion is 2026-06.

What conditions does trial NCT05497531 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Hepatobiliary Cancer.

What interventions are being tested in trial NCT05497531?

The interventions under investigation include: ctDNA Blood Collection (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05497531?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05497531 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.